These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 2553657)

  • 1. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase.
    Minami S; Akama M; Araki H; Watanabe Y; Narita H; Iyobe S; Mitsuhashi S
    J Antimicrob Chemother; 1996 Mar; 37(3):433-44. PubMed ID: 9182100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
    Satake S; Yoneyama H; Nakae T
    J Antimicrob Chemother; 1991 Aug; 28(2):199-207. PubMed ID: 1778851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
    Margaret BS; Drusano GL; Standiford HC
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():161-7. PubMed ID: 2509413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].
    Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 Mar; 33(3):453-64. PubMed ID: 8040111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of acquired β-lactamases in
    Glen KA; Lamont IL
    Microbiol Spectr; 2024 Oct; 12(10):e0069424. PubMed ID: 39248479
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Carbapenem resistance in Pseudomonas aeruginosa isolates: an example of interaction between different mechanisms].
    Santella G; Pollini S; Docquier JD; Almuzara M; Gutkind G; Rossolini GM; Radice M
    Rev Panam Salud Publica; 2011 Dec; 30(6):545-8. PubMed ID: 22358400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey.
    Bonfiglio G; Laksai Y; Franchino L; Amicosante G; Nicoletti G
    J Antimicrob Chemother; 1998 Dec; 42(6):697-702. PubMed ID: 10052891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa.
    Walsh F; Bracher S; Turner P; Amyes S
    Chemotherapy; 2007; 53(6):407-9. PubMed ID: 17934261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients.
    Ballestero S; Fernández-Rodríguez A; Villaverde R; Escobar H; Pérez-Díaz JC; Baquero F
    J Antimicrob Chemother; 1996 Jul; 38(1):39-45. PubMed ID: 8858455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.
    Zincke D; Balasubramanian D; Silver LL; Mathee K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):936-45. PubMed ID: 26621621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.